Harlan Robins on How T-cell Focused COVID Vaccines Can Move Us Toward Endemicity episode artwork

EPISODE · Feb 16, 2022 · 31 MIN

Harlan Robins on How T-cell Focused COVID Vaccines Can Move Us Toward Endemicity

from Mendelspod Podcast · host Theral Timpson

Harlan Robins is the Chief Scientific Officer at Adaptive Biotechnologies in Seattle. In 2014, Harlan and his brother Chad co-founded Adaptive as a spinout from the Fred Hutchinson Cancer Center where Harlan had served as the head of computational biology. Adaptive has been developing what they call "immune medicine" mainly in the area of cancer. When the corona virus pandemic hit, they came out with the world’s first T cell-based COVID diagnostic. The test has garnered them a lot of data on T cell response to COVID. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Episode metadata supplied by the publisher feed · Published Feb 16, 2022

Embed this episode

NOW PLAYING

Harlan Robins on How T-cell Focused COVID Vaccines Can Move Us Toward Endemicity

0:00 31:11

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Mendelspod Podcast?

This episode is 31 minutes long.

When was this Mendelspod Podcast episode published?

This episode was published on February 16, 2022.

Can I download this Mendelspod Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!